NASDAQ:EGLT Egalet (EGLT) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free EGLT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0080▼$0.008050-Day Range$0.01▼$0.3352-Week Range$0.03▼$1.57VolumeN/AAverage Volume853,425 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Egalet alerts: Email Address Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Egalet Stock (NASDAQ:EGLT)Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.Read More Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. EGLT Stock News HeadlinesAugust 16, 2022 | prnewswire.comThe Worldwide Opioids Industry is Expected to Reach $6.29 Billion by 2027 - PR NewswireAugust 16, 2022 | finance.yahoo.comInsights on the Opioids Global Market to 2027 - Increasing Investments in R&D in Healthcare Presents Opportunities - Yahoo FinanceAugust 12, 2022 | businesswire.comGlobal Opioids Market (2022 to 2027) - Players Include Pfizer, Purdue Pharmaceuticals, Rhodes Technologies and Sun Pharmaceutical Industries - ResearchAndMarkets.com - Business WireJuly 28, 2022 | finance.yahoo.comDrug Taste Masking and Taste Assessment Services and Technologies Markets, 2035 - Yahoo FinanceJuly 28, 2022 | globenewswire.comDrug Taste Masking and Taste Assessment Services and Technologies Markets, 2035 - GlobeNewswireJuly 26, 2022 | businesswire.comGlobal Drug Taste Masking and Taste Assessment Services and Technologies Market Report 2022-2035 - ResearchAndMarkets.com - Business WireJuly 25, 2022 | prnewswire.comGlobal Drug Taste Masking and Taste Assessment Services and Technologies Market Report 2022: Oral Solid Dosage Market is the Largest Segment, Anticipated to Reach Over $900 Billion by 2027 - PR NewswireMay 20, 2022 | businesswire.comGlobal Osteoporosis Therapeutics Market to 2027 - Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth - ResearchAndMarkets.com - Business WireMay 20, 2022 | benzinga.comGlobal Osteoporosis Therapeutics Market to 2027 - Rising Prevalence of Osteoporosis in Post-menopausal Wo - BenzingaMay 15, 2022 | globenewswire.comOsteoporosis Therapeutics Market to Top US$ 14 Bn Valuation by 2026: Fact.MR Analysis - GlobeNewswireMarch 17, 2022 | businesswire.comGlobal Opioid Market Outlook to 2028: Oxycodone Segment is Estimated to Grow at Significant Pace During Forecast Period - ResearchAndMarkets.com - Business WireMarch 14, 2022 | benzinga.comNasal Spray Market Size Global Industry Share, Industry Growth, Competitive Landscape, Recent Development - BenzingaMarch 14, 2022 | globenewswire.comNasal Spray Market Size Global Industry Share, Industry Growth, Competitive Landscape, Recent Developments, Regional Outlook and Forecast by 2029 - GlobeNewswireMarch 10, 2022 | streetinsider.comForm 10-K Assertio Holdings, Inc. For: Dec 31 - StreetInsider.comMarch 10, 2022 | globenewswire.comPostoperative Pain Management Market growth is predicted at 5% CAGR to reach a valuation of US$ 57.8 Bn by 2031 - GlobeNewswireMarch 10, 2022 | benzinga.comPostoperative Pain Management Market growth is predicted at 5% CAGR to reach a valuation of US$ 57.8 Bn b - BenzingaJanuary 4, 2022 | prnewswire.comChemomab Therapeutics Names Jack Lawler Vice President of Global Clinical Development Operations - PRNewswireJanuary 4, 2022 | finance.yahoo.comJohn Varian Joins Acorda Therapeutics Board of Directors - Yahoo FinanceOctober 26, 2021 | finance.yahoo.comThe FDA Missed Egalet's PDUFA Date, But Investors Should Not Be WorriedOctober 18, 2021 | axios.comThe $10,000 suppository - AxiosOctober 14, 2021 | globenewswire.comWorldwide Opioid Drugs Industry to 2029 - by Drug Type, - GlobeNewswireOctober 13, 2021 | finance.yahoo.comNasal Sprays Market Report 2021-2028 | Size, Share, Growth Factors, Restraining Factors, Competitive Landscape, Revenue, Forecast Analysis - Yahoo FinanceAugust 6, 2021 | markets.businessinsider.comGlobal Osteoporosis Therapeutics Market to Reach $13.1 Billion by 2024 - Markets InsiderAugust 5, 2021 | finance.yahoo.comGlobal Osteoporosis Therapeutics Market to Reach $13.1 Billion by 2024 - Yahoo FinanceSee More Headlines Receive EGLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Egalet and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2018Today5/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EGLT CUSIPN/A CIK1586105 Webwww.egalet.com Phone610-833-4200FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Robert S. Radie (Age 55)Pres, CEO & Director Mr. Stanley J. Musial (Age 57)Exec. VP, CFO & Sec. Dr. Mark Strobeck (Age 47)Exec. VP & COO Ms. Barbara A. Carlin (Age 43)Sr. VP & Chief Accounting Officer Dr. Karsten Lindhardt M.Sc. (Age 46)Ph.D., Chief Scientific Officer Key CompetitorsGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All Competitors EGLT Stock Analysis - Frequently Asked Questions How were Egalet's earnings last quarter? Egalet (NASDAQ:EGLT) announced its earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.06. The specialty pharmaceutical company earned $7.44 million during the quarter, compared to analysts' expectations of $8.64 million. What other stocks do shareholders of Egalet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Egalet investors own include Novavax (NVAX), Cara Therapeutics (CARA), TG Therapeutics (TGTX), Ocular Therapeutix (OCUL), Trevena (TRVN), Overstock.com (OSTK), Portola Pharmaceuticals (PTLA) and Synergy Pharmaceuticals (SGYP). This page (NASDAQ:EGLT) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressShocking $16T Elon Musk Crypto LeakCrypto 101 Media[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Egalet Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.